Glenmark Pharma gains 3% on positive data in phase 2a study of GBR 830 for skin disease News News / News 6 years ago 572 Views comments "This data provides great opportunity for us to partner this molecule and from now we will start getting active in trying to close an out-licensing de... Read more
News India#39;s position on resolving matters with Pakistan bilaterally not changed: MEA News / News - 6 years ago
News Nifty likely to head towards 10,600; 5 stocks which can give up to 15% return News / News - 6 years ago
News Nilekaniâs comeback may allay investor fears, but all eyes on next Infosys CEO News / News - 6 years ago
News IT raids: Shivakumar apologises to CM Siddaramaiah for mother#39;s remarks News / News - 6 years ago
Comments